Association Between Asymptomatic Hyperuricemia and Risk of Arthritis, Findings from a US National Survey 2007-2018

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Feb 12

PMID 38346893

Authors

Zhenguo Liang

Dongze Wu

Hua Zhang

Jieruo Gu

Affiliations

Soon will be listed here.

Abstract

Background: Arthritis is thought to be closely related to serum uric acid. The study aims to assess the association between asymptomatic hyperuricemia (AH) and arthritis.

Methods: A multistage, stratified cluster was used to conduct a cross-sectional study of adult US civilians aged≥20 years from the 2007-2018 National Health and Nutrition Examination Survey. Participants with hyperuricemia and without hyperuricemia prior to gout were included. A questionnaire was used to determine whether participants had arthritis and the type of arthritis. Logistic regression was used to investigate the association between hyperuricemia and arthritis.

Result: During the past 12 years, the percentage of participants with arthritis changed from 25.95% (22.53%-29.36%) to 25.53% (21.62%-29.44%). The prevalence of osteoarthritis (OA) increased from 8.70% (95% CI: 6.56% to 10.85%) to 12.44% (95% CI: 9.32% to 15.55%), the prevalence of AH changed from 16.35% (95% CI: 14.01% to 18.40%) to 16.39% (95% CI: 13.47% to 19.30%). Participants with AH were associated with onset of arthritis (OR=1.34, 95% CI: 1.07 to 1.69), but the association was muted after adjusting demographic and socioeconomic factors. For participants aged 40-49 years, AH is associated with incident arthritis (OR=1.96, 95% CI: 1.23 to 2.99) and the relationship remained after adjusting for education level, income to poverty ratio, body mass index, diabetes, hypertension and smoking (OR=2.00, 95% CI: 1.94 to 3.36). Compared with male, female participants with AH are more likely to develop arthritis, especially in OA (OR=1.35, 95% CI: 1.14 to 1.60).

Conclusion: Our data identified AH as the risk factor for incident arthritis, especially for OA, which might be exaggerated in aged population and female population.

Citing Articles

Relationship between serum carotenoids and osteoarthritis or degenerative arthritis: A cross-sectional study using the National Health and Nutrition Examination Survey.

Zhu B, Li G, Wu K, Luo Q, Wu X Nutr J. 2025; 24(1):25.

PMID: 39948622 PMC: 11823093. DOI: 10.1186/s12937-025-01087-8.

Gender differences in the prognostic impact of uric acid in patients with heart failure and preserved ejection fraction.

Wu X, Li J, Xu Z, Feng Y BMC Cardiovasc Disord. 2025; 25(1):29.

PMID: 39825228 PMC: 11742201. DOI: 10.1186/s12872-025-04481-6.

Hyperuricemia and its related diseases: mechanisms and advances in therapy.

Du L, Zong Y, Li H, Wang Q, Xie L, Yang B Signal Transduct Target Ther. 2024; 9(1):212.

PMID: 39191722 PMC: 11350024. DOI: 10.1038/s41392-024-01916-y.

Association between triglyceride glycemic index and gout in US adults.

Li T, Zhang H, Wu Q, Guo S, Hu W J Health Popul Nutr. 2024; 43(1):115.

PMID: 39113110 PMC: 11308556. DOI: 10.1186/s41043-024-00613-4.

References

Krasnokutsky S, Oshinsky C, Attur M, Ma S, Zhou H, Zheng F . Serum Urate Levels Predict Joint Space Narrowing in Non-Gout Patients With Medial Knee Osteoarthritis. Arthritis Rheumatol. 2017; 69(6):1213-1220. PMC: 5449226. DOI: 10.1002/art.40069. View

FitzGerald J, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles A . 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020; 72(6):744-760. PMC: 10563586. DOI: 10.1002/acr.24180. View

Liote F, Pascart T . From hyperuricaemia to gout: what are the missing links?. Nat Rev Rheumatol. 2018; 14(8):448-449. DOI: 10.1038/s41584-018-0040-6. View

DeBoer M, Gurka M . Low sensitivity for the metabolic syndrome to detect uric acid elevations in females and non-Hispanic-black male adolescents: an analysis of NHANES 1999-2006. Atherosclerosis. 2011; 220(2):575-80. PMC: 3321243. DOI: 10.1016/j.atherosclerosis.2011.11.033. View

Kuo C, Grainge M, Zhang W, Doherty M . Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11):649-62. DOI: 10.1038/nrrheum.2015.91. View

Bortoluzzi A, Furini F, Scire C . Osteoarthritis and its management - Epidemiology, nutritional aspects and environmental factors. Autoimmun Rev. 2018; 17(11):1097-1104. DOI: 10.1016/j.autrev.2018.06.002. View

Tsuruta N, Imafuku S, Narisawa Y . Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients. J Dermatol. 2017; 44(12):1349-1352. DOI: 10.1111/1346-8138.13968. View

Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z . Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 2008; 35(9):1859-64. View

Murphy L, Cisternas M, Greenlund K, Giles W, Hannan C, Helmick C . Defining Arthritis for Public Health Surveillance: Methods and Estimates in Four US Population Health Surveys. Arthritis Care Res (Hoboken). 2016; 69(3):356-367. DOI: 10.1002/acr.22943. View

10.

Raucci F, Iqbal A, Saviano A, Minosi P, Piccolo M, Irace C . IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation. Pharmacol Res. 2019; 147:104351. DOI: 10.1016/j.phrs.2019.104351. View

11.

Dalbeth N, L Gosling A, Gaffo A, Abhishek A . Gout. Lancet. 2021; 397(10287):1843-1855. DOI: 10.1016/S0140-6736(21)00569-9. View

12.

Yokose C, Chen M, Berhanu A, Pillinger M, Krasnokutsky S . Gout and Osteoarthritis: Associations, Pathophysiology, and Therapeutic Implications. Curr Rheumatol Rep. 2016; 18(10):65. DOI: 10.1007/s11926-016-0613-9. View

13.

Chen-Xu M, Yokose C, Rai S, Pillinger M, Choi H . Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6):991-999. PMC: 6536335. DOI: 10.1002/art.40807. View

14.

Neogi T, Krasnokutsky S, Pillinger M . Urate and osteoarthritis: Evidence for a reciprocal relationship. Joint Bone Spine. 2018; 86(5):576-582. PMC: 6531371. DOI: 10.1016/j.jbspin.2018.11.002. View

15.

Hunter D, Bierma-Zeinstra S . Osteoarthritis. Lancet. 2019; 393(10182):1745-1759. DOI: 10.1016/S0140-6736(19)30417-9. View

16.

Joosten L, Crisan T, Bjornstad P, Johnson R . Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2019; 16(2):75-86. PMC: 7075706. DOI: 10.1038/s41584-019-0334-3. View

17.

Chiou A, England B, Sayles H, Thiele G, Duryee M, Baker J . Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality. Arthritis Care Res (Hoboken). 2019; 72(7):950-958. PMC: 6842395. DOI: 10.1002/acr.23926. View

18.

Musumeci G, Aiello F, Szychlinska M, Di Rosa M, Castrogiovanni P, Mobasheri A . Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and progression. Int J Mol Sci. 2015; 16(3):6093-112. PMC: 4394521. DOI: 10.3390/ijms16036093. View

19.

Roddy E, Zhang W, Doherty M . Are joints affected by gout also affected by osteoarthritis?. Ann Rheum Dis. 2007; 66(10):1374-7. PMC: 1994292. DOI: 10.1136/ard.2006.063768. View

20.

Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M . Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2016; 76(4):632-638. DOI: 10.1136/annrheumdis-2016-209467. View